ClinicalTrials.gg
Status unknownNCT04252144Updated Feb 3, 2022

Study of Dietary Patterns and Food Diversity in Russian GERD Patients

An interventional study of Dietary assessment in Gastroesophageal; Reflux With Esophagitis, Gastroesophageal Reflux and GERD, sponsored by Russian Academy of Medical Sciences. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Russian Academy of Medical Sciences · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the study is to assess food diversity and dietary patterns in Russian GERD patients

Read the detailed description

The study of dietary patterns may provide complex vision of an association between consumption of specific foods, or groups of food products and manifestations of gastroesophageal reflux disease (symptoms: heartburn and acid regurgitation; endoscopic findings - oesophagitis). Only limited data on this matter are published to the moment and they predominantly concerns outcomes of gastroesophageal reflux disease (oesophageal adenocarcinoma or Barrett's oesophagus). Taking into the consideration that earlier studies found significant differences in consumption of nutrients in different world regions, new data on food patterns of dietary patterns in Russian GERD patients could partly fill in the gap of knowledge on this particular matter.

02

Conditions studied

  • Gastroesophageal; Reflux With Esophagitis
  • Gastroesophageal Reflux
  • GERD
  • Heartburn
  • Non-erosive Reflux Disease
  • Esophagitis

Keywords

  • food diversity
  • dietary pattern
  • healthy eating pattern
  • oesophagitis
  • GERD
03

In context

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

This study's planned enrollment of 150 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.

Browse Esophagitis, Peptic studies →

Lead sponsor

Russian Academy of Medical Sciences is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • willingness to participate (signed the form);
  • willingness to follow all the required procedures;

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding females;
  • Neoplasms, current or by the medical history (except local skin cancer successfully treated);
  • History of chest or abdominal surgery, except appendectomy and cholecistectomy (in case when no consequences of these operations like adhesive disease of the abdominal cavity are present);
  • Co-morbid conditions which can influence or mask the symptoms of GERD (including, but not limited to: ischaemic heart disease, severe pulmonary disease, severe depression or anxiety, etc);
  • the use of concomitant medications that may influence on the symptoms or other manifestations of gastroesophageal reflux disease: NSAIDs, (except topic ones for no longer than 2 weeks), any medications directly influencing mood and function of central nervous system (antidepressants, anxiolytics, anti-anxiety agents, anticonvulsant etc) at the moment of enrolment and during a 2 half-life period of the certain drug;
  • the use of medications that influence gastric secretion at the time of enrolment and during 2 week before it;
  • any condition of the patient which makes the participation of the patient in the study unreasonable or put him at risk of the condition's exacerbation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    GERD

    Patients with verified gastroesophageal reflux disease

    Procedure: Dietary assessment

  • Other
    Contol

    Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination

    Procedure: Dietary assessment

Interventions

  • ProcedureDietary assessment

    Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.

    Also known as: Food frequency questionnaire

06

What researchers measure

Primary outcomes

  1. grains consumption diversity

    Mean number of different types of grains consumed in form of different foods or food products a month during 12-months period

    Time frame: a month

  2. meat consumption diversity

    Mean number of different types of meat consumed in form of different foods or food products a month during 12-months period

    Time frame: a month

  3. poultry consumption diversity

    Mean number of different types of poultry consumed in form of different foods or food products a month during 12-months period

    Time frame: a month

  4. fish consumption diversity

    Mean number of different types of fish consumed in form of different foods or food products a month during 12-months period

    Time frame: a month

  5. flour consumption diversity

    Mean number of different types of flours consumed in form of different foods or food products a month during 12-months period

    Time frame: a month

  6. vegetables consumption diversity

    Mean number of different types of vegetables consumed as is or in the form of different foods or food products

    Time frame: a month

  7. Fruits consumption diversity

    Mean number of different types of fruits consumed as is or in the form of different foods or food products

    Time frame: a month

  8. Fats consumption diversity

    Mean number of different types of fats consumed in the form of different foods or food products a month by 12 month period

    Time frame: a month

Secondary outcomes

  1. GERD-associated dietary pattern

    complex of nutrients and/or foods (food products) which correlates with presence of GERD. The correlation coefficients for each food item is range in the order of significance and direction of the relationship and in accordance to the amount of the product consumed, than is formed to the integral mean.

    Time frame: a year

07

Study locations

1 of 1 sites recruiting
  • Gastroenterology and Hepatology, FRC Nutrition and Biotechnology
    Moscow, 115446, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study data may be shared by request after study completion, except subjects' personal (identification) information

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After the study completion, available for 2 years

Access criteria: By request

Data sharing details ↗ · ion.ru

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Sep 2023, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Feb 5, 2020
StartActual
Jan 30, 2020
Primary completionEst.
Sep 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04252144
Lead sponsor
Russian Academy of Medical Sciences
Collaborators
Russian Science Foundation
Responsible party
Vasily Isakov (MD, PhD, Professor, AGAF, Russian Academy of Medical Sciences) — Principal investigator
First posted
Feb 5, 2020
Start date
Jan 30, 2020
Primary completion
Sep 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Feb 3, 2022

Study contacts

Sergey Morozov, MD, PhD
Contact
morosoffsv@mail.ru
+79104681801
Vasily Kropochev, MD
Contact
followkropochev@ya.ru
+74997943572
Vasily Isakov, MD, PhD, Professor, AGAF
study chair · FRC nutrition and biotechnology
Sergey Morozov, MD, PhD
principal investigator · FRC Nutrition and Biotechnology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion